UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 12, 2013
ImmunoGen, Inc.
(Exact name of registrant as specified in its charter)
|
Massachusetts |
|
0-17999 |
|
04-2726691 |
|
(State or other |
|
(Commission File |
|
(IRS Employer |
830 Winter Street, Waltham, MA 02451
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (781) 895-0600
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 5.07. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
At the 2013 annual meeting of shareholders of ImmunoGen, Inc. (the “Company”) held on November 12, 2013 (the “2013 Annual Meeting”), shareholders fixed the number of Directors constituting the full Board of Directors at nine. The voting results were as follows:
|
For: |
|
73,458,369 |
|
|
|
Against |
|
1,550,854 |
|
|
|
Abstain |
|
495,437 |
|
|
|
Broker Non-Votes |
|
0 |
|
|
At the 2013 Annual Meeting, shareholders elected nine Directors as follows:
|
|
|
FOR |
|
WITHHELD |
|
BROKER NON-VOTES |
|
|
Joseph J. Villafranca, PhD |
|
56,788,073 |
|
403,507 |
|
18,313,080 |
|
|
Nicole Onetto, MD |
|
56,840,427 |
|
351,153 |
|
18,313,080 |
|
|
Stephen C. McCluski |
|
56,790,533 |
|
401,047 |
|
18,313,080 |
|
|
Richard J. Wallace |
|
56,624,830 |
|
566,750 |
|
18,313,080 |
|
|
Daniel M. Junius |
|
56,738,149 |
|
453,431 |
|
18,313,080 |
|
|
Howard H. Pien |
|
56,500,241 |
|
691,339 |
|
18,313,080 |
|
|
Mark Goldberg, MD |
|
56,694,566 |
|
497,014 |
|
18,313,080 |
|
|
Dean J. Mitchell |
|
56,655,180 |
|
536,400 |
|
18,313,080 |
|
|
Kristine Peterson |
|
56,838,684 |
|
352,896 |
|
18,313,080 |
|
At the 2013 Annual Meeting, shareholders voted to approve, on an advisory basis, the compensation paid to the our named executive officers, as described in our proxy statement (the “say-on-pay vote”) as follows:
|
For: |
|
55,568,718 |
|
|
|
Against |
|
1,459,846 |
|
|
|
Abstain |
|
163,016 |
|
|
|
Broker Non-Votes |
|
18,313,080 |
|
|
At the 2013 Annual Meeting, shareholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2014 as follows:
|
For: |
|
74,772,667 |
|
|
|
Against |
|
304,182 |
|
|
|
Abstain |
|
427,811 |
|
|
|
Broker Non-Votes |
|
0 |
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
ImmunoGen, Inc. |
|
|
(Registrant) |
|
|
|
|
Date: November 13, 2013 |
/s/ Daniel M. Junius |
|
|
|
|
|
Daniel M. Junius |
|
|
President and Chief Executive Officer |